Improved Glycemic Control With Surgical Tx of Obesity in Teens
WEDNESDAY, March 14, 2018 -- Surgical treatment of severe obesity in adolescents with type 2 diabetes is associated with better glycemic control and weight reduction than medical therapy, according to a study published online March 12 in JAMA Pediatrics.
Thomas H. Inge, M.D., Ph.D., from the University of Colorado Denver in Aurora, and colleagues compared glycemic control in cohorts of severely obese adolescents with type 2 diabetes undergoing medical and surgical interventions. Data were obtained for participants in the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS), who underwent a primary bariatric surgical procedure, and the Treatment Options of Type 2 Diabetes in Adolescents and Youth (TODAY) consortia, who were randomized to metformin alone or in combination with rosiglitazone or an intensive lifestyle intervention. Data from 30 Teen-LABS participants and 63 TODAY participants were analyzed.
The researchers found that the mean hemoglobin A1c concentration decreased from 6.8 to 5.5 percent in Teen-LABS and increased from 6.4 to 7.8 percent in TODAY participants during two years. In Teen-LABS there was a 29 percent decrease in body mass index compared with baseline, while a 3.7 percent increase was seen in TODAY. During two-year follow-up, 23 percent of Teen-LABS participants required a subsequent operation.
"These data support the need for a well-designed, prospective controlled study to define the role of surgery for adolescents with type 2 diabetes, including health and surgical outcomes," the authors write.
Several authors disclosed financial ties to the pharmaceutical and weight loss industries.
© 2020 HealthDay. All rights reserved.
Posted: March 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.